US vs. Europe: Two Very Different Cannabis Opinion Stories

October 5, 2026

Photo by Philipp via Unsplash.

Gallup has been asking Americans the same legalization question for decades, and for the first time since 2020, the number moved in a direction that matters. The October 2025 poll put support for legal cannabis at 64%, down four points from the year before, snapping what had been a remarkably flat run between 68% and 70% for five straight years. A four-point drop sounds modest until you notice where it came from: Republican support alone fell 13 points in twelve months, to 40%, while Democrats sat at 85% and independents at 66%, both essentially unmoved. This wasn't a national mood shift. It was one party rethinking its position while the other two stayed put.

Put that next to Europe and the comparison gets awkward fast, because Europe doesn't have a number like this to report. There's no EU-wide poll on legalization because there's no EU-wide cannabis policy to poll opinion about -- Germany is mid-experiment with nonprofit clubs, the UK is debating without a bill on the table, and everywhere from Portugal to Poland runs its own version of decriminalized, tolerated, or flatly illegal. Lining these two regions up side by side doesn't settle the question of who's more pro-cannabis. It exposes something more interesting: the US has built a single, repeatable mechanism for measuring national opinion on this drug, and Europe, by design and by fragmentation, hasn't.

America's Plateau: A Political Story, Not a Cultural One

Gallup's methodology hasn't changed, which is what makes the October 2025 reading worth taking seriously rather than dismissing as noise. Interviews ran October 1-16, 2025, and the topline number -- 64% support for legalization -- is the lowest Gallup has recorded since 2019, before a wave of states built out adult-use markets. For context, the figure held in a tight 68-70% band every single year from 2020 through 2024, the kind of stability pollsters rarely see on a question this politically coded. Then it broke, and it broke in exactly one place.

Republican support fell to 40% in 2025, a 13-point collapse in a single survey cycle. Democrats stayed at 85%. Independents stayed at 66%. There is no version of this data where the decline is distributed across the electorate -- it's concentrated entirely in one party's shifting posture, which points toward messaging and political identity rather than anyone updating their views on the drug itself.

That's where Pew's parallel data becomes useful as a reality check. Pew doesn't ask the blunt legalize-or-not question; it asks whether cannabis should be legal for medical use, legal for any use, or illegal under all circumstances. Framed that way, support for some form of legality sits at 88%, and only around 10% of American adults back full criminalization. That's a strikingly different number from Gallup's 64%, and the gap isn't a contradiction -- it's a measurement artifact. Gallup's question forces a binary on a policy landscape most Americans actually hold more granular views about. When you let people distinguish medical from recreational, support barely budges. When you force an up-or-down vote on broad legalization, the answer gets dragged around by partisan mood of the moment. The decline is real as a data point. It's not evidence that Americans are souring on cannabis.

Record Use, Ballot Fights, and the 2026 Midterms

Photo by Element5 Digital via Pexels.

Here's the number that should complicate any Republican-cooling narrative: Gallup's August 2026 release found 17% of Americans report currently smoking cannabis, a record high in the poll's tracking. For comparison, just 11% report smoking cigarettes. That crossover -- more Americans smoking cannabis than tobacco -- has never happened before in Gallup's data. Opinion on the legal question may be wobbling in one party, but actual behavior is climbing across the board, which is its own kind of answer to whether the drug-war framing is landing with the people who'd actually have to live under it.

The ballot calendar for 2026 is where this tension gets tested directly. Massachusetts and Idaho both have cannabis legalization measures headed for voters, putting a deep-blue state and a deep-red one through the same binary choice in the same cycle. Idaho in particular is a useful stress test: it's one of the last holdout states with no medical or adult-use program at all, and it's attempting this vote at the exact moment national Republican enthusiasm for legalization is falling off a cliff.

Gubernatorial races in Kansas and Iowa are litigating cannabis policy on the campaign trail in real time, with candidates in both states forced to stake out positions rather than duck the question -- a sign that even in states without a ballot measure, cannabis has become a live wedge issue rather than background noise. That's new. For most of the past decade, cannabis legalization tracked toward bipartisan consensus and quietly dropped out of campaign rhetoric because there wasn't much daylight left to argue over.

The softening of Republican support doesn't necessarily kill red-state measures outright, but it removes the cushion that made legalization campaigns in conservative states feel close to inevitable. Idaho's measure now has to win over a Republican base that's 13 points less enthusiastic than it was a year ago, even as national usage data shows cannabis has never been more normalized in daily life. Those two trends -- rising use, cooling Republican sentiment -- are set to collide directly at the ballot box in November.

Europe Has No Single Opinion to Measure

Photo by Christian Lue via Unsplash.

Ask what Europeans think about cannabis legalization and the honest answer is: which Europeans, and legalization of what, exactly? There is no EU-level legalization and no harmonized medical prescribing pathway anywhere in the bloc. Brussels touches cannabis in only three narrow lanes -- pharmaceutical standards for medicines derived from it, Novel Foods regulation governing CBD ingestibles, and the bloc's shared obligations under a long-standing UN drug control treaty that still frames cannabis as a controlled substance for member states. None of that adds up to a policy. It adds up to a set of constraints within which 27 different countries do 27 different things.

The European Union Drugs Agency's 2026 European Drug Report confirms cannabis is the continent's most-used illicit drug by a wide margin, with an estimated 8.7% of adults aged 15 to 64 -- roughly 25 million people -- having used it in the past year. That's a real, continent-wide figure, and it's worth sitting with the fact that it's lower than the US's 17% current-smoking rate, even though Europe's legal frameworks are, on paper, more restrictive in nearly every member state. Americans are using more cannabis under looser aggregate law. Europeans are using less under tighter aggregate law. If legality were the only variable driving consumption, you'd expect the opposite.

What's actually driving the European number is a patchwork so uneven that averaging it into one continental figure obscures more than it reveals. The Netherlands has run its coffee-shop tolerance policy for decades without ever formally legalizing cultivation or wholesale supply. Portugal decriminalized personal possession of all drugs some years ago and treats use as an administrative, not criminal, matter. Germany just created a club-based possession and cultivation system. Meanwhile Poland, Hungary, and Russia maintain real criminal penalties for possession. There's no Gallup-style annual tracking poll because there's no single policy question to ask -- each country's relationship to cannabis is its own separate experiment running on its own separate timeline, and lumping them into a European average flattens differences that are, legally speaking, the entire story.

Germany's Club Model: A Live Test Case

Photo by Pavel Danilyuk via Pexels.

Germany is the closest thing Europe has to a live legalization case study, and it's worth watching closely precisely because it isn't going the way either side predicted. The Cannabisgesetz took effect April 1, 2024, allowing adults to possess limited quantities and to grow or acquire cannabis through nonprofit Cannabis Social Clubs -- membership-based cooperatives that cultivate for their own members rather than selling to the public. A planned second pillar of the law, covering licensed commercial retail sales, was supposed to follow. As of mid-2026, it still hasn't materialized, leaving the club system as the only legal supply channel in the country.

The club rollout itself has been slow by any measure. As of August 2026, German authorities had approved 455 clubs, up from 413 that spring, with another 896 applications still sitting in review. That pace of approval, against a backlog nearing a thousand pending applications, tells you the bureaucratic apparatus wasn't built for the volume of interest it's now processing.

Even full approval of every pending application wouldn't come close to solving the supply problem. Modelling based on current club capacity suggests that if every single pending application were approved tomorrow, the club system would still cover only 3.5% to 4.3% of estimated national cannabis demand. That's not a rounding error -- it's a structural ceiling built into a model that caps club membership and limits per-club cultivation, regardless of how many clubs eventually open.

Unsurprisingly, people are finding their own workarounds. A post-legalization survey of 1,500 Germans found about 10% had tried growing cannabis at home, a legal option under the same law but one that sidesteps the club system entirely and suggests plenty of consumers aren't waiting around for a club seat to open up. For neighboring countries watching Germany as a potential template, the lesson emerging isn't that legalization works or doesn't -- it's that legalizing possession and building functional, scaled supply are two entirely different projects, and Germany has only finished the first one. That's shaping the conversation in Austria, France, and elsewhere as much as any abstract debate over legalization's merits.

Britain's Split Verdict

Photo by dimitrisvetsikas1969 via Pixabay.

Britain's public is, for once, genuinely split rather than quietly leaning one way while the headline number suggests otherwise. YouGov's April 2026 poll found 47% of Britons support legalizing cannabis against 43% opposed -- a four-point gap that's well within the range where a single well-timed news cycle could flip the topline. That's a real shift from a decade ago, when opposition ran well ahead of support in most UK polling on the question.

What makes the UK number genuinely distinct from the US picture is what sits alongside it. The same polling environment that shows near-even support for legalization also finds 57% of Britons describing cannabis as harmful to regular users, including 22% who call it very harmful. In the US, rising support for legalization has tracked alongside declining perception of risk -- the two numbers moved in the same direction, reinforcing each other. In Britain, they haven't. People are increasingly willing to legalize something a majority still considers harmful, which is a more complicated, arguably more honest position than treating legalization support as a referendum on whether a drug is safe.

None of this has translated into legislative movement. The UK has no legal adult-use framework and no medical dispensing system comparable to Germany's club-based model or to American state-level dispensaries -- cannabis remains a Class B controlled substance, and medical access, where it exists at all, runs through a narrow, restrictive prescribing pathway that most patients never successfully navigate. Public opinion has moved well ahead of Westminster on this, and there's no sign Parliament is in any hurry to close that gap.

The partisan structure is different too. In the US, cannabis opinion maps almost perfectly onto party identification -- Democrats near-unanimous in support, Republicans sharply divided and recently cooling, independents steady in the middle. UK polling doesn't break down nearly as cleanly along party lines, which makes the issue harder for any single party to own, and probably explains why no British government has felt real pressure to legislate one way or the other.

Why the Comparison Matters

Photo by Manuella Schorchit via Pexels.

The structural difference between these two regions is the real story, more than any single percentage point. The US treats cannabis as a single national referendum question, asked and re-asked every year by the same pollster using the same wording, which means shifts -- like this year's Republican collapse -- show up immediately and legibly. Europe treats cannabis as dozens of separate, slow-moving national experiments, each running on its own legislative clock, with no equivalent mechanism to aggregate sentiment even if you wanted to. That's not a flaw in European data collection. It's a direct consequence of cannabis policy being a national competency the EU has no treaty basis to override.

Germany's experience is the clearest proof that legal reform and accessible supply are not the same achievement. Approving possession and club cultivation got Germany headlines about legalization, but 4% market coverage, even in a best-case scenario with every pending club approved, is nowhere close to displacing an illicit market that's had decades to entrench itself. Anyone treating Germany's 2024 law as a finished reform is reading the press release, not the modelling.

On the American side, the fact that the entire softening in support traces to one party suggests the next phase of this debate isn't going to be fought with new evidence about health effects or criminal justice outcomes -- that data hasn't changed. It's going to be fought over framing, messaging, and which political coalition owns the issue heading into mid-term campaigns.

For anyone in the export or research side of this industry with money riding on European expansion, the signal to track isn't an aggregate EU sentiment number, because that number doesn't meaningfully exist. Watch Germany's long-delayed second law on commercial retail, and watch whether UK parliamentary momentum ever catches up to YouGov's 47%. Those two specific, concrete developments will tell you more about where European cannabis policy is actually headed than any continent-wide opinion survey ever could.

Line the raw percentages up and the US looks like the settled market and Europe looks like the cautious one -- 64% support for legalization against a continent still arguing over coffee-shop tolerance and club cultivation caps. The usage data flips that story entirely. Seventeen percent of Americans report currently smoking cannabis; Europe's entire past-year usage figure, across all 27 member states, sits at 8.7%. More Americans are smoking cannabis right now than Europeans report using it at all in a given year, even though European law remains, almost everywhere, the stricter regime on paper. Legal status and actual behavior have decoupled on both continents, just in different directions.

The deeper divide isn't acceptance versus rejection of the drug. It's that the US has a functioning, repeatable national conversation about legality -- one pollster, one question, asked the same way year after year -- while Europe is still laying the plumbing, country by country, to even have that conversation at all. Germany is building the pipes. Britain has the public opinion but not the legislation. The rest of the continent hasn't started. None of that is a judgment on which approach is better; it's just a different stage of institutional development, and conflating the two because they're both called legalization misses what's actually happening in each place.

The thing worth actually watching isn't another Gallup release or another EUDA report. It's whether Germany's second law on commercial retail sales finally appears, and whether Idaho and Massachusetts voters deliver a verdict in November that either confirms or complicates the Republican pullback. Whichever of those two moves first -- a functioning German retail market, or a clear American ballot signal -- is going to become the template the other side studies next.